The REALYSA study aims to improve knowledge about lymphomas and the lives of patients with lymphomas. Thanks to the large number of patients who participate, it allows sub-studies to be conducted simultaneously on specific research questions. One of its sub-studies, called Glyphosate Mutation, involves patients who have diffuse large B-cell lymphoma and have been exposed to pesticides prior to diagnosis.
Why is this study being implemented?
Some studies show that exposure to pesticides, especially glyphosate, could increase the risk of developing B-cell lymphoma. Glyphosate is a widely used herbicide, to which some people can be exposed in their work (agriculture, green spaces) but also in daily life, through food or the environment. This study is set up to better understand whether and how glyphosate can cause DNA changes that can lead to lymphoma.
What are the objectives of the study?
The objective of this study is to better understand the effects of glyphosate on human DNA. It aims to identify genetic mutations that may be linked to glyphosate exposure, particularly in lymphoma patients. The aim is to improve knowledge of the mechanisms that can lead to lymphoma, in order to better assess the risks and, ultimately, contribute to prevention and better patient care.
How will the study be carried out?
The study will be based on the analysis of data from the medical records of patients participating in REALYSA. The biological samples taken during your follow-up in REALYSA will be analysed by researchers at the University of Nevada, Las Vegas (USA), who will carry out genetic analyses.They will work with data and samples from B-cell lymphoma patients participating in the REALYSA study.
This data will not make it possible to establish a link with the identity of the patients because it is pseudonymised: the first and last names of each person are replaced by a unique number assigned when they are included in REALYSA.
LYSARC and its partners cannot link this number to a patient’s identity. LYSARC and its partners cannot link this number to a patient’s identity.
The Glyphosate Mutation study is scheduled to begin in April 2026.
A L’ATTENTION DES PATIENTS PARTICIPANT À REALYZA
What does this study mean for you?
This study is only for patients participating in REALYSA who have B-cell lymphoma who have reported lifetime exposure to pesticides. If you are in this situation and agree to have your data and biological samples used for this study, it has no direct implications for you. In particular, you will not have to answer any additional questionnaire compared to what is already planned as part of your participation in REALYSA.
What should you do about this study?
There are two options:
- You are not opposed to the use of your data in the context of this study:
- In this case, you don’t have to do anything.
- You wish to object to the use of your data in the context of this study:
- In this case, you must inform the doctor who offered you to participate in the REALYSA study or DESCAR-T. You can also notify your decision by writing an email to the following address: dpo@lysarc.org .
You will find detailed information on your rights to object to the use of your data on page 12 of the information notice that was given to you when you agreed to participate in REALYSA or DESCAR-T.